Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.46 |
| ▸ | HTR3A | P46098 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.45 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17241716 | 0.85 | CA9 (0.59) | KDM4EPKMOPRM1OPRD1KMT2A | |
| SCHEMBL17242622 | 0.85 | KDM4E (0.56) | KDM4EPKMKMT2AMAPTALDH1A1 | |
| SCHEMBL7655012 | 0.84 | KDM4E (0.72) | KDM4EPKMKMT2ACA9MAPT | |
| SCHEMBL17242609 | 0.84 | DDR1 (0.56) | KDM4EPKMOPRM1OPRD1KMT2A | |
| SCHEMBL17242523 | 0.82 | KDM4E (0.56) | KDM4EPKMOPRM1OPRD1KMT2A | |
| SCHEMBL17242600 | 0.79 | PKM (0.49) | KDM4EPKMOPRM1OPRD1KMT2A | |
| SCHEMBL17242492 | 0.78 | KDM4E (0.41) | KDM4EKMT2AALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL31207290 | 0.78 | PKM (0.62) | KDM4EPKMOPRM1OPRD1KMT2A | |
| SCHEMBL17242548 | 0.77 | KDM4E (0.53) | KDM4EPKMOPRM1OPRD1KMT2A | |
| SCHEMBL17242582 | 0.76 | KDM4E (0.43) | KDM4EKMT2AMAPTALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170137387-A1 | PHARMACOLOGICALLY ACTIVE QUINAZOLINEDIONE DERIVATIVES | ORION CORPORATION (FI) | 2017-05-18 | — | — | US | disclosed |
| EP-3140301-A1 | PHARMACOLOGICALLY ACTIVE QUINAZOLINEDIONE DERIVATIVES | Orion Corporation (FI) | 2017-03-15 | — | — | EP | disclosed |
| WO-2015169999-A1 | PHARMACOLOGICALLY ACTIVE QUINAZOLINEDIONE DERIVATIVES | ORION CORPORATION (FI) | 2015-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137387-A1 | PHARMACOLOGICALLY ACTIVE QUINAZOLINEDIONE DERIVATIVES | GABRB1, GABRB3, GABRB2 | KDM4E 1998/4885PKM 3154/4885OPRM1 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.